Alpha Tau Medical Schedules Annual Shareholder Meeting for June 2025

Alpha Tau Medical Ltd ( (DRTS) ) has shared an update.

Alpha Tau Medical Ltd. has announced its upcoming annual general meeting of shareholders, scheduled for June 17, 2025, at its headquarters in Jerusalem, Israel. The meeting will address several key proposals, including the re-election and election of directors, approval of warrant issuances, re-appointment of the company’s accounting firm, and amendments to the director compensation package. These decisions are crucial for the company’s governance and strategic direction, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.

Spark’s Take on DRTS Stock

According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.

Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.

To see Spark’s full report on DRTS stock, click here.

More about Alpha Tau Medical Ltd

Alpha Tau Medical Ltd. operates in the medical industry, focusing on innovative cancer treatment solutions. The company is known for its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology, which aims to provide highly effective and targeted cancer treatments.

Average Trading Volume: 45,180

Technical Sentiment Signal: Hold

Current Market Cap: $236.6M

Find detailed analytics on DRTS stock on TipRanks’ Stock Analysis page.